Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Completed · Phase 1/Phase 2

Conditions studied: Graft vs Host Disease

In brief

The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment. The research is being conducted at up to 10 clinical research sites in the US.

Key facts

Study ID

NCT00032292

Run by

Facet Biotech

People needed

34

Starts

2002-03-01

Expected to finish

2006-08-01

Last updated by the study team

2012-03-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• Stanford University Medical Center — Stanford, California, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Duke University — Durham, North Carolina, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.